agent

(redirected from Erythropoiesis-stimulating agent)
Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Acronyms, Wikipedia.

agent

a person representing a business concern, esp a travelling salesman

Agent

 

in Soviet civil law, a party in a contract of agency. The agent’s duties include the performance of specified legal acts, for example, contracts of sale and management of property, in the name of and on the account of a principal party. The agent may be a legally competent (sui juris) citizen or a legal person (if this is allowed by the latter’s charter or statute). The actions performed by the agent directly generate, change, or extinguish rights and obligations of the principal.

The agent is bound to perform the agency in exact conformity with the principal’s instructions, carry out the agency personally, although in instances provided for by law the responsibilities may be transferred to another person (art. 68 of the RSFSR Civil Code), inform the principal upon demand of progress in performing the agency, submit a report on performance of the agency, and transfer to the principal any property obtained in connection with performance of the agency.

agent

One who is empowered to enter into binding transactions on behalf of another (usually called the principal).

agent

(networking)
In the client-server model, the part of the system that performs information preparation and exchange on behalf of a client or server. Especially in the phrase "intelligent agent" it implies some kind of automatic process which can communicate with other agents to perform some collective task on behalf of one or more humans.

agent

A software routine that waits in the background and performs an action when a specified event occurs. For example, agents could transmit a summary file on the first day of the month or monitor incoming data and alert the user when a certain transaction has arrived. Agents are also called "intelligent agents," "personal agents" and "bots." See mobile agent, bot and workflow.
References in periodicals archive ?
Possible reasons for switching a patient between erythropoiesis-stimulating agents may include patient preference, injection site pain, hypersensitivity to one of the erythropoiesis-stimulating agents, stability/storage, dosing interval, lack of response to one of the erythropoiesis-stimulating agents and the support provided by the manufacturer.
Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia.
Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
Hemoglobin (Hb) variability, in which Hb levels fluctuate above and below the target range over short periods of time, frequently occurs in patients with chronic kidney disease (CKD) Stages 1 to 5 and who are receiving erythropoiesis-stimulating agents (ESAs).
Treatment with erythropoiesis-stimulating agents (ESAs) is the hallmark of anemia management in patients on hemodialysis.
In one analysis of 240 patients with functioning kidney transplants, only 36% of those with Hgb levels below 10 g/dL had reported iron studies, and 60% were not receiving an erythropoiesis-stimulating agent (Mix et al., 2003).
Table 1 Case Study: Laboratory Results 2007 September October November December ESA dose, U/wk 18,000 21,000 25,000 27,000 IV iron dose, mg/wk 31.25 31.25 31.25 31.25 Hb, g/dL 11.5 10.9 10.7 10.4 Serum ferritin, ng/mL 650 760 840 1025 TSAT, % 28 27 26 24 2008 January February ESA dose, U/wk 15,000 15,000 IV iron dose, mg/wk 125 125 Hb, g/dL 11.3 11.8 Serum ferritin, ng/mL 800 620 TSAT, % 27 30 Note: ESA = erythropoiesis-stimulating agent; IV = intravenous; Hb = hemoglobin; TSAT = transferrin saturation.
This was an especially timely topic given the new data on the efficacy of IV iron therapy at moderately elevated serum ferritin levels (Coyne et al., 2007) and the controversy erupting from recent studies surrounding erythropoiesis-stimulating agents (ESAs).
Celgene Corporation (CELG) and Acceleron Pharma (XLRN) announced that Celgene has submitted a Marketing Authorization Application to the European Medicines Agency for luspatercept for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes-associated anemia who have ring sideroblasts, require red blood cell transfusions and have received or are not eligible for erythropoiesis-stimulating agents, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions.
"The use of intravenous iron therapy has escalated in the treatment of anemia of CKD in order to optimize hemoglobin outcomes with the use of erythropoiesis-stimulating agents," Dyer and her colleagues concluded.
The introduction of erythropoiesis-stimulating agents (ESA) has led to a dramatic reduction in blood transfusion requirements and has been associated with improved quality of life [1, 2].
One approach is to use erythropoiesis-stimulating agents or intravenous iron for pre-existing anemia (10).

Full browser ?